ACE 527

Drug Profile

ACE 527

Alternative Names: ACAM-2010; ACE-537; ACE527; ETEC vaccine - Cambridge Biostability; ETEC vaccine - Zymenex; HolaVax; HolaVax-ETEC vaccine

Latest Information Update: 28 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acambis
  • Developer ACE BioSciences; TD Vaccines A/S
  • Class Escherichia coli vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Escherichia coli infections

Most Recent Events

  • 29 Mar 2010 Phase-II clinical trials in Escherichia coli infections in USA (PO)
  • 09 Nov 2009 ACE BioSciences has been acquired by Zymenex A/S
  • 19 May 2009 ACE 527 is in active development for Escherichia coli infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top